Skip to main content
. 2021 Feb 27;3(1):dlab003. doi: 10.1093/jacamr/dlab003

Figure 7.

Figure 7.

Point prevalence estimates of resistance against carbapenems in E. coli and K. pneumoniae by country in the Asia-Pacific region, stratified by surveillance strategy (laboratory-based surveillance, population-based surveillance): (a) imipenem, (b) ertapenem, (c) meropenem. The horizontal line indicates the 95% CI. An asterisk (*) indicates the study only included ESBL isolates.